Voyageur Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Aug '25 Aug 31, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020	2019 - 2015
Cost of Revenue	0.01	-	-	-	-	-	Upgrade
Gross Profit	-0	-	-	-	-	-	Upgrade
Selling, General & Admin	1.74	1.1	0.99	1.45	1.23	0.71	Upgrade
Operating Expenses	2.51	1.51	1.22	1.61	1.97	1.14	Upgrade
Operating Income	-2.51	-1.51	-1.22	-1.61	-1.97	-1.14	Upgrade
Other Non Operating Income (Expenses)	-0.61	-0.18	-0.12	-0.15	-0.08	-0	Upgrade
EBT Excluding Unusual Items	-3.12	-1.7	-1.35	-1.75	-2.05	-1.14	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	-0.01	-	-	Upgrade
Asset Writedown	-0.01	-0.01	-0.05	-	-	-	Upgrade
Other Unusual Items	-	-	-0	0	-	-	Upgrade
Pretax Income	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14	Upgrade
Net Income	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14	Upgrade
Net Income to Common	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14	Upgrade
Shares Outstanding (Basic)	156	138	131	108	95	71	Upgrade
Shares Outstanding (Diluted)	156	138	131	108	95	71	Upgrade
Shares Change (YoY)	14.68%	5.46%	21.03%	13.89%	34.24%	22.58%	Upgrade
EPS (Basic)	-0.02	-0.01	-0.01	-0.02	-0.02	-0.02	Upgrade
EPS (Diluted)	-0.02	-0.01	-0.01	-0.02	-0.02	-0.02	Upgrade
Free Cash Flow	-2.71	-0.47	-1.17	-2	-2.09	-0.43	Upgrade
Free Cash Flow Per Share	-0.02	-0.00	-0.01	-0.02	-0.02	-0.01	Upgrade
EBITDA	-2.51	-1.51	-1.22	-1.6	-1.97	-0.98	Upgrade
D&A For EBITDA	0	0	0	0.01	0.01	0.15	Upgrade
EBIT	-2.51	-1.51	-1.22	-1.61	-1.97	-1.14	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.